Shares of BioDelivery Sciences International Inc. (NASDAQ:BDSI) were up 3.6% during mid-day trading on Friday . The company traded as high as $2.91 and last traded at $2.90, with a volume of 496,807 shares traded. The stock had previously closed at $2.80.

A number of analysts have recently issued reports on BDSI shares. Zacks Investment Research lowered shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research report on Tuesday, July 12th. Cantor Fitzgerald downgraded BioDelivery Sciences International from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $9.00 to $5.00 in a report on Wednesday, May 11th. Piper Jaffray Cos. restated a “sell” rating and issued a $4.00 price objective on shares of BioDelivery Sciences International in a report on Wednesday, August 10th. FBR & Co restated a “buy” rating on shares of BioDelivery Sciences International in a report on Thursday, May 12th. Finally, Janney Montgomery Scott restated a “hold” rating and issued a $4.00 price objective on shares of BioDelivery Sciences International in a report on Tuesday, July 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. BioDelivery Sciences International has an average rating of “Hold” and an average target price of $8.25.

The company’s 50-day moving average is $2.53 and its 200 day moving average is $2.94. The company’s market cap is $154.48 million.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.31). The business had revenue of $5 million for the quarter, compared to analysts’ expectations of $3.35 million. The firm’s revenue for the quarter was up 194.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.37) EPS. Analysts forecast that BioDelivery Sciences International Inc. will post ($1.14) EPS for the current year.

In related news, Director William B. Stone sold 16,000 shares of the business’s stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $2.57, for a total transaction of $41,120.00. Following the transaction, the director now owns 122,675 shares in the company, valued at approximately $315,274.75. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.